CN117460512A - Idh突变体抑制剂及其用途 - Google Patents

Idh突变体抑制剂及其用途 Download PDF

Info

Publication number
CN117460512A
CN117460512A CN202280040684.0A CN202280040684A CN117460512A CN 117460512 A CN117460512 A CN 117460512A CN 202280040684 A CN202280040684 A CN 202280040684A CN 117460512 A CN117460512 A CN 117460512A
Authority
CN
China
Prior art keywords
compound
compounds
pharmaceutically acceptable
general formula
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280040684.0A
Other languages
English (en)
Chinese (zh)
Inventor
谢雨礼
樊后兴
钱立晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN117460512A publication Critical patent/CN117460512A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280040684.0A 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途 Pending CN117460512A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021106613945 2021-06-15
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN117460512A true CN117460512A (zh) 2024-01-26

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280040684.0A Pending CN117460512A (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Country Status (10)

Country Link
US (1) US20240208978A1 (https=)
EP (1) EP4356914A4 (https=)
JP (1) JP2024524933A (https=)
KR (1) KR20240021774A (https=)
CN (1) CN117460512A (https=)
AU (1) AU2022294860A1 (https=)
BR (1) BR112023024454A2 (https=)
CA (1) CA3217608A1 (https=)
MX (1) MX2023013664A (https=)
WO (1) WO2022262784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
PL2900675T3 (pl) * 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
JP6387360B2 (ja) * 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2764523T3 (es) * 2015-07-27 2020-06-03 Lilly Co Eli Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes
CN109311863B (zh) 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
ES2941631T3 (es) 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Also Published As

Publication number Publication date
KR20240021774A (ko) 2024-02-19
JP2024524933A (ja) 2024-07-09
WO2022262784A1 (zh) 2022-12-22
US20240208978A1 (en) 2024-06-27
AU2022294860A1 (en) 2024-01-25
CA3217608A1 (en) 2022-12-22
EP4356914A1 (en) 2024-04-24
MX2023013664A (es) 2024-01-08
BR112023024454A2 (pt) 2024-02-06
EP4356914A4 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
WO2022222921A1 (zh) 含哌嗪结构的parp抑制剂、其制备方法及医药用途
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
WO2023138541A1 (zh) 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
CN118027016A (zh) Parg抑制剂及其制备方法和用途
CN112243437B (zh) 含丙烯酰基的核转运调节剂及其用途
CN117460512A (zh) Idh突变体抑制剂及其用途
TW201815793A (zh) 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
CN113880804A (zh) 新型苯并咪唑化合物
CN115768775B (zh) Idh突变体抑制剂及其用途
RU2860311C2 (ru) Ингибитор мутанта idh и его применение
US12600714B2 (en) Substituted pyrazinecarboxamide compounds for treating diseases related to EGFR mutation
CN111349077B (zh) 一种哒嗪衍生物及其制备方法和医药用途
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN117616026B (zh) 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
WO2022063299A1 (zh) 用作dhodh抑制剂的1,2,4-三唑酮衍生物
CA3285927A1 (en) Kif18a inhibitor
WO2024213111A1 (zh) Parp抑制剂、其制备方法及医药用途
JP2025540298A (ja) Ｈｄａｃ阻害剤およびその使用
CN121517424A (zh) PI3Kα抑制剂及其制备方法和医药用途
WO2022228511A1 (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
HK40081475A (en) Synthesis of novel ep4 antagonist and use in cancers and inflammations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination